Clinical Trials Browser

Phase 2 × Recruiting × HER2-low Hormone Receptor Positive Breast Cancer × Clear all

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Phase 2 Recruiting

HER2-low Hormone Receptor Positive Breast Cancer